Knockdown of MTHFD1L can enhance the sensitivity of HCC cells to sorafenib by increase the level of oxidative stress, indicating that MTHFD1L in the folate cycle is a promising therapeutic target. The gene discussed is MTHFD1L; the disease is hepatocellular carcinoma.